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(HCV) infection vary considerably between studies. The aim of
this systematic review was to characterize case deﬁnitions for
recent HCV and explore the heterogeneity in studies performed
to date.
Methods: A systematic literature search of MEDLINE, SCOPUS,
and ISI Web of Knowledge was performed covering all studies
of recent HCV infection cited between January 2000 and June
2011. The criteria used by each study to deﬁne cases of recent
HCV infection were extracted, structured, and analyzed.
Results: Overall, 195 articles were included, with 87% (n = 169)
providing a clear case deﬁnition for recent HCV infection. The
most frequently used individual criteria for deﬁning a case
included HCV antibody seroconversion (77%), alanine amino-
transferase (ALT) elevation (68%), and HCV RNA detection
(63%). In studies using HCV antibody seroconversion, the window
period between the last negative and the ﬁrst positive antibody
test varied widely across studies (4 weeks to 4 years). Consider-
able diversity was also observed with respect to the ALT thresh-
old used to characterize ALT elevations, ranging from 2 to 20
times the upper limit of normal. HCV antibody seroconversion
was used as a single criterion in 41% of the studies, while all other
studies used at least two criteria (range: 2–9). Epidemiology/sur-
veillance studies mostly used a more sensitive case deﬁnition,
whereas treatment studies, natural history studies, and diagnosis
studies used more speciﬁc case deﬁnitions.
Conclusions:Marked heterogeneity in case deﬁnitions for recent
HCV infection was observed. Although a single case deﬁnition for
recent HCV is not warranted, a degree of standardization within
speciﬁc study categories would enable improved cross-study
comparison and more uniform evaluation of HCV prevention
and management strategies.
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inject drugs.Our knowledge of recently acquired hepatitis C virus (HCV) infec-
tion has been hampered for two reasons: (1) the majority of cases
with recent HCV infection are asymptomatic [1–3], and (2) the
identiﬁcation and follow-up of those at the highest risk of infec-
tion, such as people who inject drugs (PWID), have been difﬁcult.
Despite these limitations, a large number of studies have been
performed in the setting of acute or recent HCV infection. Case def-
initions for recent HCV in these studies are highly variable.
Although guidelines are available for the diagnosis, management,
and treatment of HCV infection [4,5], these guidelines do not con-
tain any recommendations of case deﬁnitions for recent HCV
infection.
Accurate case deﬁnitions for recent HCV infection are essen-
tial for ensuring standardized surveillance of HCV incidence and
enabling the assessment of the impact of policies designed to
reduce HCV transmission [6,7]. Well-deﬁned cases of recent
HCV infection can also provide valuable insight into HCV patho-
genesis, which is important for vaccine design. Lastly, early iden-
tiﬁcation of recent HCV infection provides the opportunity for
enhanced HCV treatment outcomes [8,9].
Traditionally, the acute-phase of HCV infection is deﬁned as
6 months following infection acquisition [1,10]. This deﬁnition
is generally based on evidence that the majority of individuals
who spontaneously clear HCV (73–86%) do so within the ﬁrst
6 months following infection (reviewed in [8,11]). There is no
deﬁnitive test available to distinguish acute or recent HCV infec-
tion from chronic infection. The most accurate case deﬁnition for
identifying recent HCV infection is the detection of HCV RNA in
an individual with documented HCV antibody seroconversion,
preferably with a narrow window period [2,12]. However, detec-
tion of HCV antibody seroconversion needs longitudinal monitor-
ing of at-risk individuals, which is difﬁcult in practice. Other
criteria such as marked serum alanine aminotransferase (ALT)
elevation or acute hepatitis clinical symptoms (particularly jaun-
dice) have been suggested as the secondary criteria to diagnose
acute HCV infection [1,4,12,13]. However, these additional crite-
ria are insufﬁcient as only 15–30% of patients develop a symp-
tomatic acute hepatitis illness [3,14] and ALT elevation does not
differentiate acute HCV infection from exacerbation of chronic
HCV infection or other causes of acute hepatitis in a patient with
chronic HCV infection [3]. Detection of HCV RNA with negative
HCV antibody (and subsequent seroconversion) accurately
diagnoses very recent HCV infection [4,15], but is uncommon in
clinical practice.12 vol. 57 j 1349–1360
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Previous studies attempting to review existing evidence in
natural history or treatment of recent HCV infection reported
considerable heterogeneity in case deﬁnitions for recent HCV
infection [8,9,16]. The aim of this systematic review was to char-
acterize case deﬁnitions for recent HCV infection and explore the
heterogeneity in studies performed to date.Methods
This systematic review was written according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) statement [17]. Given the
PRISMA statement was originally developed for systematic reviews of studies
evaluating healthcare interventions, components of this statement have been
customized to ﬁt the scope of the current systematic review.
Eligibility criteria
All primary research papers investigating any aspect of recent HCV infection were
included if they were:
(a) published in English
and
(a) conducted on human individuals
The case deﬁnition of recent HCV infection was chosen to include individuals
in both the acute and early chronic phases. A broader deﬁnition of recent HCV
infection is consistent with evidence that spontaneous HCV clearance occurs up
to 2 years following infection acquisition [16] and that HCV treatment response
may be enhanced in both acute and early chronic HCV infection [8].
Information sources
A literature search of MEDLINE (Pubmed), SCOPUS, and ISI Web of Knowledge
was performed on June 20th, 2011, covering all studies published and cited sinceStudy category Description 
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Fig. 1. Criteria used to categorize selected studies based on the main objectives of t
1350 Journal of Hepatology 2012January 1, 2000. Reference lists of selected articles and the relevant review arti-
cles found during the initial search were hand searched and forward citation
checks were carried out to identify further potentially relevant studies.
Search strategies
Given the various terminology used in studies referring to recent HCV infection,
we used a wide range of search terms in search strategy to ensure all relevant
studies were captured. The search strategy used was ‘‘acute hepatitis C’’ OR
‘‘acute HCV’’ OR ‘‘acute-phase hepatitis C’’ OR ‘‘acute phase hepatitis C’’ OR
‘‘acute-phase HCV’’ OR ‘‘acute phase HCV’’ OR ‘‘early hepatitis C’’ OR ‘‘early
HCV’’ OR ‘‘recent hepatitis C’’ OR ‘‘recent HCV’’ OR ‘‘incident hepatitis C’’ OR ‘‘inci-
dent HCV’’ OR ‘‘newly acquired HCV OR ‘‘newly acquired hepatitis C’’. The search
strategy was employed by looking for search terms in the title, abstract or key-
words of the studies. Indexed subject heading terms were not used because no
speciﬁc term was found in MeSH and EMTREE thesauruses for recent HCV
infection.
Study selection
Citations found during the primary search were merged using EndNote X4
(Thomson Reuters, New York, NY, USA). The abstracts of potentially eligible arti-
cles were reviewed to determine the relevance, of which relevant full texts were
retrieved and examined.
Studies reported only in abstract form were excluded, given an insufﬁcient
case deﬁnition of recent HCV infection often reported in abstracts. Case reports
and small case series reporting on fewer than 10 study participants were also
excluded to avoid the inclusion of uncharacteristic or non-representative case
deﬁnitions. Moreover, studies were excluded if they presented a subgroup or
reanalysis of data from another included study unless they either used a different
case deﬁnition of recent HCV infection or were classiﬁed in a different study cat-
egory, as described below and in Fig. 1.
Data collection and analysis
All criteria used by each study for case deﬁnition of recent HCV infection were
extracted. Based on each set of criteria, the number of individuals enrolled was
recorded (if this information was provided in the paper). In addition, the
following information was extracted from each article: country, study name (ifical characteristics of individuals with recent HCV infection 
infection or risk factors associated with recent HCV acquisition 
recent HCV infection 
cidence of recent HCV infection 
CV in recent HCV infection 
nce in recent HCV infection 
ith spontaneous clearance in recent HCV infection 
ogression of recent HCV infection to chronic phase and 
ction among affected or exposed people 
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iasis, lipid disorders, etc) associated to physiopathology 
n 
 recent HCV infection 
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he studies.
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• Not primary research, n = 100
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• Available only in abstract, n = 205
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n = 195
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of acute hepatitis C
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Primary identified citations
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Excluded due to unclear or insufficient definition
Fig. 2. Flow diagram detailing review process and study selection.
JOURNAL OF HEPATOLOGYapplicable), total number of study participants, gender distribution, age mean/
median, main mode of HCV acquisition, and HIV positive distribution.
The selected studies were categorized according to the main objectives of the
study: (1) epidemiology/surveillance; (2) natural history; (3) treatment; and (4)
diagnosis. Some studies having more than one main objective were included in
more than one category. The criteria used to deﬁne four categories are summa-
rized in Fig. 1.
The frequency of individual criteria and criteria sets used to deﬁne a case was
calculated disaggregating by study categories. Given that acute HCV infection is
traditionally deﬁned as the ﬁrst 6 months following infection acquisition [1,10],
the frequency of using 6-month or shorter seroconversion window period versus
using longer than 6-month seroconversion window period was compared among
various study. Among studies using ALT elevation as a case deﬁnition criterion,
the frequency of using an ALT threshold of 10 times the upper limit of normal
(ULN) and higher versus using a threshold of lower than 10 times ULN was com-
pared among various study categories.
The extracted criteria for case deﬁnition of recent HCV infection were
recorded and structured in Microsoft Excel 2007 (Microsoft, Redmond, WA,
USA). All quantitative analyses were subsequently performed using Stata version
12.0 (StataCorp, College Station, TX, USA).
Results
Study selection
The studies included and excluded through the review process are
summarized in Fig. 2. Overall, the initial search yielded 2211 cita-
tions. Of these, 2035 were excluded for the following reasons:
non-relevant or duplicate articles (identiﬁed through searching
multiple databases), not primary research papers, repeating
reports, available only in abstract, and case reports or low sample
size (Fig. 2). The remaining 176 citationswere retained for full text
review. Nineteen further articles were added through backward/
forward citation check. Following the full text review, 26 articles
(13.3%) were excluded because no clear or sufﬁcient case deﬁni-
tion for recent HCV infection was provided in the full text. Thus,
169 articles were included for data analysis [18–186].
Study characteristics
The characteristics of included studies are summarized in Table 1.
A total number of 16,814 individuals with recent HCV infectionJournal of Hepatology 2012were enrolled in the studies ranging from 10 to 2075 (mean:
99; median: 36). Within study populations, the main mode of
HCV acquisition was injecting drug use (51 studies, 38%) followed
by unsafe sexual intercourse (27 studies, 20%). Fifty-four studies
(32%) exclusively enrolled people from one high risk population
among which the major populations included men who have
sex with men (16 studies, 36%), PWID (15 studies, 34%), and
hemodialysis patients (13 studies, 29%). Moreover, about one
third of the studies (25 studies, 34%) enrolled exclusively HCV
mono-infected individuals, but in 29 studies (40%) all enrolled
individuals were HIV co-infected.
Among the 169 studies included in this systematic review, 71
studies (42%) focused on epidemiology/surveillance, 61 (36%) on
natural history, 39 (23%) on treatment, and 18 (11%) on diagnosis.
Twenty studies (12%) were categorized in more than one study
category.
Various terms were used to describe recent infection, with the
most common being ‘‘acute HCV infection’’ (140 studies, 83%).
Other terms included ‘‘incident HCV infection’’ (14 studies, 8%),
‘‘newly acquired HCV infection’’ (seven studies, 4%), ‘‘recent
HCV infection’’ (four studies, 2%), ‘‘early HCV infection’’ (three
studies, 2%), and ‘‘HCV seroconversion’’ (one study, 1%). Use of
‘‘incident HCV infection’’ was restricted to epidemiology/surveil-
lance studies but the other terms were used in all four study
categories.Criteria of case deﬁnition for recent HCV infection
The frequency of each criterion used for recent HCV infection
case deﬁnition is presented in Table 2. The three most frequently
used criteria included HCV antibody seroconversion (131 studies,
77%), ALT elevation (115 studies, 68%), and HCV RNA detection
(107 studies, 63%).
Within studies using HCV antibody seroconversion as a case
deﬁnition criterion, the reported window period of HCV exposure
(time between the last negative antibody test and the ﬁrst posi-
tive antibody test) was very wide, ranging from 4 weeks to
4 years (Fig. 3A). Many studies among those using HCV antibodyvol. 57 j 1349–1360 1351
Table 1. Characteristics of the included studies.
Number of studies (%)
Total number = 169
Male (%)a,*
Mean ± SD
Median (Inter-quartile range)
63.4 ± 23.9
61.3 (46.7-79.3)
Age (mean or median)b
≤30 yr 
31 to 40 yr
≥41 yr 
20 (16.4)
63 (51.6)
39 (32.0)
Main mode of HCV acquisitionc,**
Injecting drug use
Unsafe homosexual or heterosexual intercourse
Medical procedures
Haemodialysis
Occupational exposure in healthcare workers
Blood transfusion 
Unknown risk factor
51 (38.4)
27 (20.3)
23 (17.3)
14 (10.5)
10 (7.5)
4 (3.0)
6 (4.5)
HIV co-infectiond
No HIV/HCV co-infected participants
HIV/HCV co-infected participants included (1-99%)
All HIV/HCV co-infected participants
25 (34.3)
19 (26.0)
29 (39.7)
Data was provided by: a132 studies (78.1%); b122 studies (72.2%); c133 studies (78.7); d73 studies (43.2%).
⁄Data presented as percentage.
⁄⁄Percentages do not total 100% because in two studies more than one risk factor was reported as the main mode of HCV acquisition among enrolled individuals.
Table 2. Individual frequency of each criterion used in the studies for case
deﬁnition of recent HCV infection.
Number of studies 
(%)
Total number = 169
HCV antibody seroconversion 131 (77.5)
ALT elevation 115 (68.0)
HCV RNA positive 107 (63.3)
Exposure
Definite exposure
Probable exposure
Both or not reported
46 (27.2)
14 (30.4)
4 (8.7)
28 (60.9)
Clinical symptoms
Fever or jaundice + general symptoms
General symptoms ± fever or jaundice
Both used in various sets of criteria
40 (23.7)
13 (32.5)
23 (57.5)
4 (10.0)
HCV antibody positive 40 (23.7)
HCV RNA positive + 
HCV antibody negative
32 (18.9)
Increasing HCV antibody titre 8 (4.7)
HCV RNA fluctuation >10 fold (1 log10) 2 (1.2)
Reviewseroconversion as a case deﬁnition criterion (53 studies, 41%) did
not report the window period length. Among the studies report-
ing the window period length, the most commonly used were 6
and 12 months. Among the studies categorized under one study
category and reporting the window period of HCV exposure
(n = 69), 38% of epidemiology/surveillance studies used a window
period of <6 months as compared to 80% of treatment studies
(p = 0.003) and 100% of diagnosis studies (p = 0.005).
ALT elevation was also commonly used to identify individuals
with recent HCV infection. However, considerable diversity was1352 Journal of Hepatology 2012observed with respect to the ALT threshold used, ranging from
2 to 20 times ULN. Many studies among those using ALT elevation
as a case deﬁnition criterion (22 studies, 19%) did not report a
threshold value. Among the studies reporting the ALT elevation
threshold, the most common level was 10 times ULN (Fig. 3B).
Among the studies categorized under one study category and
reporting ALT level threshold as ULN (n = 71), 41% of epidemiol-
ogy/surveillance studies used an ALT threshold of 10 times ULN
or higher as compared to 89% of natural history studies
(p <0.001).
HCV antibody seroconversion was the only criterion used in
some studies as a single criterion for a case deﬁnition of recent
HCV infection. Criteria other than HCV antibody seroconversion
(e.g., HCV RNA positive, ALT elevation, etc.) were used within case
deﬁnitions comprising two or more criteria (Tables 3 and 4).
While 69 studies (41%) used one criteria set, the other 100 studies
(59%) used more than one criteria set ranging from 2 to 9 sets.
HCV antibody seroconversion was used in 55 studies (42%) as
a single criterion and in 76 studies (58%) in conjunction with
other criteria to deﬁne a case (Table 3). The largest number of
study subjects was identiﬁed with HCV antibody seroconversion
as a single criterion (mean: 69 per study). A more restricted cri-
teria set, with HCV antibody seroconversion in conjunction with
HCV RNA detection and ALT elevation, was the second most fre-
quently used criteria set, which was used in 25 studies (19%), and
identiﬁed an average of 53 individuals in each study.
A total number of 43 criteria sets were used as case deﬁnitions
for recent HCV infection. The most frequently used criteria sets in
all studies and in each study category are presented in Table 4.
HCV antibody seroconversion as a single criterion was the most
frequently used case deﬁnition in epidemiology-surveillance
studies which was used in almost half of the studies in this cat-
egory (33 studies, 46%). In natural history studies, HCV antibody
seroconversion was also the most commonly used case deﬁnition
(15 studies, 25%). However, the frequency of using HCV RNAvol. 57 j 1349–1360
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Fig. 3. Heterogeneity in case deﬁnitions for recent HCV infection among the studies using HCV antibody seroconversion or ALT elevation as a case deﬁnition
criterion. (A) Window period of HCV exposure (the time between the last negative antibody test and the ﬁrst positive antibody test) in 131 studies using HCV antibody
seroconversion for case deﬁnition of recent HCV infection; (B) ALT level threshold in 115 studies using ALT elevation for case deﬁnition of recent HCV infection. ULN, the
upper limit of normal.
Table 3. The frequency of using HCV antibody seroconversion as a single criterion or in conjunction with other criteria for case deﬁnition of recent HCV infection in
the studies.
Number of studies (%)
Total number = 131
Number of individuals identi-
fied using the criteria set*
Total number (mean)
Single Seroconversion 55 (42.0) 2345 (69.0)a
Double Seroconversion + HCV RNA positive 22 (16.8) 615 (36.2)b
Seroconversion + ALT elevation 18 (13.7) 218 (27.2)c
Seroconversion + exposure 9 (6.9) 28 (9.3)d
Seroconversion + symptoms 2 (1.5) 14 (14)e
Seroconversion + increasing HCV antibody titre 1 (0.8) 1 (1)
Triple Seroconversion + HCV RNA positive + ALT elevation 25 (19.1) 1061 (53.0)f
Seroconversion + HCV RNA positive + exposure 4 (3.0) 25 (8.3)g
Seroconversion + ALT elevation + exposure 3 (2.3) Not provided
Seroconversion + ALT elevation + symptoms 2 (1.5) 26 (26)e
Seroconversion + ALT elevation + HCV RNA fluctuation 1 (0.8) 4 (4)
Quadruple Seroconversion + HCV RNA positive + ALT elevation + 
symptoms 
6 (4.6) 177 (29.5)h
Seroconversion + HCV RNA positive + ALT elevation + 
exposure 
1 (0.8) 17 (17)
Seroconversion + HCV RNA positive + symptoms + 
exposure 
1 (0.8) 1 (1)
Data was provided by: a34 studies (61.8%); b17 studies (77.3%); c8 studies (44.4%); d3 studies (33.3%); e1 study (50.0%); f20 studies (80.0%); g3 studies (75.0%); h6 studies
(100%).
⁄Data was provided by the proportion of studies reporting the number of individuals identiﬁed using each criteria set.
JOURNAL OF HEPATOLOGYdetection with initially negative HCV antibody, which detects
individuals with early acute HCV infection, was comparable (13
studies, 21%). This criteria set was also the most frequently used
case deﬁnition in diagnosis studies (7 studies, 39%). In treatment
studies more restricted criteria sets were generally used.
In 29 studies exclusively enrolling HIV co-infected partici-
pants, the most frequently used case deﬁnitions was HCV anti-
body seroconversion as a single criterion (12 studies, 41%)Journal of Hepatology 2012followed by HCV antibody seroconversion in conjunction with
ALT elevation (8 studies, 28%) and HCV RNA positive with a past
RNA/antibody negative (8 studies, 28%). In 25 studies exclusively
enrolling HCVmono-infected participants, the most common case
deﬁnition criteria sets included HCV antibody seroconversion in
conjunction with HCV RNA positive and ALT elevation (6 studies,
24%) followed by HCV antibody seroconversion (5 studies, 20%)
and HCV RNA positive plus ALT elevation (5 studies, 20%).vol. 57 j 1349–1360 1353
Table 4. The most frequently used criteria sets for case deﬁnition of recent HCV infection in the studies.
Number of studies (%) Number of individuals identi-
fied using the criteria set *
Total number (mean)
All studies
(n = 169)
Seroconversion 55 (32.5) 2345 (69.0)a
Seroconversion + HCV RNA positive + ALT elevation 25 (14.8) 1061 (53.0)b
HCV RNA positive + HCV antibody negative 23 (13.6) 625 (41.7)c
Seroconversion + HCV RNA positive 22 (13.0) 615 (36.2)d
HCV RNA positive + ALT elevation 21 (12.4) 548 (49.8)e
Epidemiology/
surveillance
(n = 71)
Seroconversion 33 (46.5) 1862 (81.0)f
HCV RNA positive + ALT elevation 11 (15.5) 316 (45.1)g
HCV RNA positive + past RNA/antibody negative 11 (15.5) 84 (28.0)h
Natural history
(n = 61)
Seroconversion 15 (24.6) 321 (64.2)i
HCV RNA positive + HCV antibody negative 13 (21.3) 216 (43.2)j
Seroconversion + HCV RNA positive + ALT elevation 10 (16.4) 263 (52.6)k
Treatment
(n = 39)
Seroconversion + HCV RNA positive + ALT elevation 11 (28.2) 97 (24.2)l
HCV RNA positive + ALT elevation + exposure 10 (25.6) 83 (27.7)m
Seroconversion 8 (20.5) 156 (39.0)n
Seroconversion + ALT elevation 8 (20.5) 59 (29.5)o
Diagnosis
(n = 18)
HCV RNA positive + HCV antibody negative 7 (38.9) 374 (53.4)p
Seroconversion + HCV RNA positive + ALT elevation + 
symptoms 3 (16.7) 103 (34.3)
q
Seroconversion 3 (16.7) 50 (16.7)q
Data was provided by: a34 studies (61.8%); b20 studies (80.0%); c15 studies (65.2%); d17 studies (77.3%); e11 studies (52.3%); f23 studies (69.7%); g7 studies (63.6%); h3
studies (27.3%); i5 studies (33.3%); j5 studies (38.5%); k5 studies (50.0%); l4 studies (36.4%); m3 studies (30.0%); n4 studies (50.0%); o2 studies (25.0%); p7 studies (100%); q3
studies (100%).
⁄Data was provided by the proportion of studies reporting the number of individuals identiﬁed using each criteria set.
ReviewDiscussion
This systematic review demonstrates that there is marked heter-
ogeneity in the case deﬁnitions used to deﬁne recent HCV infec-
tion. This heterogeneity in case deﬁnitions across studies is
particularly evident in the broad range of HCV antibody serocon-
version intervals and ALT thresholds employed in various studies.
In addition, many studies incorporated several criteria sets
within a given case deﬁnition. The ﬁndings from this study sug-
gest that a greater standardization of deﬁnitions for recent HCV
infection would be useful, particularly within speciﬁc study cate-
gories. Standardized deﬁnitions would enable improved cross-
study comparison and more uniform evaluation of HCV preven-
tion and management strategies.
HCV antibody seroconversion was the most frequently used
case deﬁnition criterion, used in 77% of studies either as a single
criterion or within a multiple criteria case deﬁnition. However,
the time between the last negative antibody test and the ﬁrst
positive antibody test (window period) differed widely across
studies. A narrower window period (e.g., 66 months) ensures
that cases are within the acute HCV infection phase, but limits
the number of enrolled cases as very frequent HCV antibody
screening is uncommon among at-risk populations. Further, it
biases the case deﬁnition toward those with a single exposure
event (e.g., occupational exposure). A broader window period
would increase case detection, enable evaluation of potentially
improved therapeutic outcomes in both acute and early chronic1354 Journal of Hepatology 2012HCV infection and should provide greater representativeness of
individuals acquiring HCV infection.
Serum ALT elevation was the second most frequently used
case deﬁnition criterion for recent HCV infection used in 68% of
studies. Although most of these studies (36%) reported serum
ALT level of 10 times ULN to characterize ALT elevation, a wide
range in ALT threshold was reported. The ALT threshold affects
both sensitivity and speciﬁcity of the criterion. A low threshold
will result in possible measurement bias by inadvertently enroll-
ing some chronic infection cases while a very high threshold will
reduce case detection. Natural history and treatment studies
tended to use higher ALT threshold ensuring greater speciﬁcity.
On the other hand, epidemiology/surveillance studies mostly
used a low ALT threshold to enhance sensitivity and thus overall
case detection. Of note, the ALT threshold has been changed twice
in the last decade for case deﬁnitions employed in the surveil-
lance of acute viral hepatitis in the United States. In 2000, the
ALT threshold was raised from 2.5 times ULN to seven times
ULN and since 2007 the threshold has been higher than 400 IU/L
[42,175,176,179].
The majority of the studies (59%) used more than one case
deﬁnition criteria set for recent HCV infection. Eight studies used
some criteria sets to deﬁne ‘‘deﬁnite/conﬁrmed cases’’ and some
others for ‘‘probable cases’’ [26,45,50,87,105,108,138,150]. In two
further studies, the criteria sets were weighted in three levels
consisting of ‘‘deﬁnite cases’’, ‘‘probable cases’’, and ‘‘possible
cases’’ [54,104]. While in all these 10 studies, ‘‘deﬁnite/conﬁrmedvol. 57 j 1349–1360
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cases’’ were deﬁned based on either HCV antibody seroconver-
sion or HCV RNA positive plus HCV antibody negative, a variety
of criteria were used for ‘‘probable cases’’ and ‘‘possible cases’’.
In addition, several studies employed different case deﬁnitions
to report ﬁndings from the same source cohort.
[50,100,108,109,124,125,158,159].
The most frequently used case deﬁnition criteria sets were dif-
ferent among study categories. While HCV antibody seroconver-
sion as a single criterion was the most frequently used case
deﬁnition in epidemiology/surveillance studies, the studies inves-
tigating diagnosis or treatment of recent HCV infection tended to
use more restricted deﬁnitions (Table 4). Moreover, different
study requirements and research questions would appear to
strongly inﬂuence case deﬁnitions. For instance, studies investi-
gating diagnosis or natural history of recent HCV infection gener-
ally need to detect individuals in the very early stage of HCV
infection. The HCV RNA detection with initial negative HCV anti-
body criterion, which meets this requirement, was found as the
most common and the second most common criterion used in
these two study categories, respectively. However, epidemiol-
ogy/surveillance studies mainly aimed at the investigation of
transmission patterns, and prevention programs generally used
HCV antibody seroconversion, often with prolongedwindow peri-
ods. Treatment studies tended to use themost restrictive case def-
initions, presumably to prevent use of suboptimal therapy among
misclassiﬁed chronic HCV cases. The Australian Trial in AcuteHep-
atitis C (ATAHC) Study, however, allowed caseswith HCV antibody
seroconversion window periods of up to 2 years in an attempt to
increase case ascertainment and to allow evaluation of therapeutic
response in both acute and early chronic HCV infection [49].
The case deﬁnition recommended by the European AIDS
Treatment Network (NEAT) Acute Hepatitis C Infection Consensus
Panel [13] states Preferred criteria, which are based on serocon-
version or positive HCV RNA and a documented negative HCV
RNA and negative HCV antibody in the previous 12 months. In
addition, they recommend the Alternative criteria, which include
a positive HCV RNA and an elevated ALT with various ALT thresh-
olds according to the history of the patients. This guideline
reports that no consensus has been reached to include a history
of HCV transmission risk factors in the alternative case deﬁnition.
No other standardized deﬁnitions have been proposed, but par-
ticularly within study categories, would provide enhanced capac-
ity for cross-study comparison. Accurate reporting of all
components within case deﬁnitions would also improve study
comparison.
Various terms were used in the studies to describe HCV infec-
tion in early stage, including ‘acute’, ‘recent’, ‘incident’, ‘newly
acquired’, and ‘early’ HCV infection. Standardization of the terms
used to describe HCV infection in early stage is needed. We sug-
gest using the term ‘acute infection’ to describe infections where
the estimated duration is less than 6 months (26 weeks). This
would include individuals with:
1. Initial detectable HCV RNA and negative HCV antibody, with
subsequent HCV antibody seroconversion;
2. Clinical symptoms (including jaundice) or an ALT higher than
10 times ULN, with other causes of acute hepatitis excluded,
and onset of symptoms or peak ALT being less than 20 weeks
prior to diagnosis (symptom onset or peak ALT are around
6 weeks from exposure);orJournal of Hepatology 20123. Asymptomatic HCV antibody seroconversion with the mid-
point between last negative HCV antibody and ﬁrst positive
HCV antibody is less than 26 weeks prior to diagnosis (unless
single exposure event can more accurately deﬁne time of
infection).
We suggest using the term ‘‘recent infection’’ for individuals
with an estimated duration of more than 6 months (26 weeks)
and less than 2 years.
The current study has some limitations. In this systematic
review, our search was limited to the studies published after
2000. Moreover, conference abstracts and grey literature were
not covered. Although a sensitive search strategy was employed
in this review, it remains possible that some studies on recent
HCV infection were not captured in our search.
Key Points 
• Marked heterogeneity in case definitions to define recent 
HCV infection was found among studies
• HCV antibody seroconversion intervals and ALT 
elevations thresholds varied widely when used as criteria 
for defining recent HCV infection. The most frequently 
used HCV antibody seroconversion intervals were 6 
months and 12 months. The most frequently used ALT 
elevations threshold was 10 times the upper limit of 
normal
• Studies in different categories mostly tended to use 
case definition criteria addressing the specific questions 
and requirements in that particular study category. 
Epidemiology/surveillance studies generally used HCV 
antibody seroconversion, often with prolonged window 
periods to enhance sensitivity. Studies investigating 
diagnosis or natural history of recent HCV infection 
generally used more specific case definitions to detect 
individuals in the very early stage of HCV infection. 
Treatment studies tended to use the most restrictive 
case definitions, presumably to prevent use of sub-
optimal therapy among misclassified chronic HCV cases
• More standardized case definitions for recent HCV within 
specific study categories are required
In summary, the current systematic review revealed considerable
heterogeneity in case deﬁnition for recent HCV infection. Studies
in different categories mostly tended to use case deﬁnition crite-
ria, which addressed the speciﬁc questions and requirements in
that particular study category. Although single case deﬁnition
for recent HCV infection is not warranted, a degree of standardi-
zation, particularly within speciﬁc study categories, would be
advantageous for clinical practice, research, and public health
surveillance. More standardized case deﬁnition(s) for recent
HCV infection will provide opportunities for comparison across
studies. From a public health point of view, utilization of standard
deﬁnition(s) to identify recently infected individuals facilitates
the introduction of standard measures to evaluate the spread of
HCV infection.vol. 57 j 1349–1360 1355
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